search
Back to results

Clinical Performance of Two Commercial, Daily Disposable Contact Lenses

Primary Purpose

Refractive Errors, Ametropia, Myopia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Delefilcon A contact lenses
Kalifilcon A contact lenses
Sponsored by
Alcon Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractive Errors focused on measuring Contact lenses

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Habitually wears soft contact lenses in both eyes at least 5 days per week and at least 10 hours per day;
  • At least 3 months of contact lens wearing experience;
  • Less than or equal to 0.75 diopter (D) astigmatism in each eye;
  • Best Corrected Visual Acuity (BCVA) better than or equal to 20/25 in each eye.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Current/previous DAILIES TOTAL1 and/or Infuse habitual lens wearer;
  • Monovision and/or multifocal lens wearer;
  • Routinely sleeps in habitual contact lenses.
  • Other protocol-defined exclusion criteria may apply.

Sites / Locations

  • Alcon Investigator 6355
  • Alcon Investigator 6418
  • Alcon Investigator 3950
  • Alcon Investigator 6614
  • Alcon Investigator 6583
  • Alcon Investigator 3382
  • Alcon Investigator 6353
  • Alcon Investigator 2786

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

DT1, then Infuse

Infuse, then DT1

Arm Description

Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.

Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.

Outcomes

Primary Outcome Measures

Least Squares Mean Distance VA (logMAR) With Study Lenses
Distance visual acuity (VA) was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity.

Secondary Outcome Measures

Full Information

First Posted
August 11, 2021
Last Updated
October 11, 2022
Sponsor
Alcon Research
search

1. Study Identification

Unique Protocol Identification Number
NCT05010512
Brief Title
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
Official Title
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
August 31, 2021 (Actual)
Primary Completion Date
October 12, 2021 (Actual)
Study Completion Date
October 12, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the clinical performance of DAILIES TOTAL1 ( DT1) contact lenses with Infuse contact lenses.
Detailed Description
Subjects will wear two products and be expected to attend 3 office visits. The individual duration of participation will be approximately 3 weeks, which includes 16 to 22 days of lens wear.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractive Errors, Ametropia, Myopia
Keywords
Contact lenses

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
112 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DT1, then Infuse
Arm Type
Other
Arm Description
Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
Arm Title
Infuse, then DT1
Arm Type
Other
Arm Description
Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
Intervention Type
Device
Intervention Name(s)
Delefilcon A contact lenses
Other Intervention Name(s)
DAILIES TOTAL1®, DT1
Intervention Description
Commercially available silicone hydrogel contact lenses used as indicated
Intervention Type
Device
Intervention Name(s)
Kalifilcon A contact lenses
Other Intervention Name(s)
Bausch + Lomb INFUSE™, Infuse
Intervention Description
Commercially available silicone hydrogel contact lenses used as indicated
Primary Outcome Measure Information:
Title
Least Squares Mean Distance VA (logMAR) With Study Lenses
Description
Distance visual acuity (VA) was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity.
Time Frame
Day 8 (-0/+3), each study lens type

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Habitually wears soft contact lenses in both eyes at least 5 days per week and at least 10 hours per day; At least 3 months of contact lens wearing experience; Less than or equal to 0.75 diopter (D) astigmatism in each eye; Best Corrected Visual Acuity (BCVA) better than or equal to 20/25 in each eye. Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: Current/previous DAILIES TOTAL1 and/or Infuse habitual lens wearer; Monovision and/or multifocal lens wearer; Routinely sleeps in habitual contact lenses. Other protocol-defined exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trial Lead, Vision Care
Organizational Affiliation
Alcon Research, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Alcon Investigator 6355
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Alcon Investigator 6418
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Facility Name
Alcon Investigator 3950
City
Bloomington
State/Province
Illinois
ZIP/Postal Code
61704
Country
United States
Facility Name
Alcon Investigator 6614
City
Franklin Park
State/Province
Illinois
ZIP/Postal Code
60131
Country
United States
Facility Name
Alcon Investigator 6583
City
Eden Prairie
State/Province
Minnesota
ZIP/Postal Code
55344
Country
United States
Facility Name
Alcon Investigator 3382
City
Wyomissing
State/Province
Pennsylvania
ZIP/Postal Code
19610
Country
United States
Facility Name
Alcon Investigator 6353
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38111
Country
United States
Facility Name
Alcon Investigator 2786
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Performance of Two Commercial, Daily Disposable Contact Lenses

We'll reach out to this number within 24 hrs